FRANKLIN LAKES, N.J.,
Sept. 12, 2017 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading
global medical technology company, today announced the launch of
BD Rhapsody, a platform for single cell analysis with the
ability to detect rare molecules responsible for biological
diversity that are often missed with whole transcriptome
profiling.
Developed using the company's patented unique molecular index
(UMI) technology, BD Rhapsody is a complete system of
reagents, instruments and software for targeted gene expression
analysis of tens of thousands of individual cells. The product was
previously in limited commercial release under the name Resolve. BD
will offer both application-specific targeted panels and enable
customers to design their own custom, targeted panels.
"Early access users have been enthusiastic about our targeted
assay solution and its superior performance compared to whole
transcriptome profiling," said Stephen
Gunstream, vice president of Genomics for BD. "These
same users have also experienced considerable sequencing cost
savings from this technology."
The BD Rhapsody platform assay offering will be rapidly expanded
over the next 12 months. Shortly after launch, customers will
be able to multiplex many samples in one run with the BD
single-cell multiplexing kit, significantly increasing sample
throughput while maintaining the low doublet rate. The platform is
also being expanded beyond RNA expression to include protein
detection, leveraging BD's extensive antibody portfolio with BD
AbSeq assays for protein expression.
"Initial data generated looks extremely positive and we believe
true understanding of complex diseases will come with the ability
to interrogate both protein and RNA in single cells
simultaneously," Gunstream added.
BD has initiated early access for AbSeq protein detection on the
BD Rhapsody system and expects commercial availability in the first
half of 2018. The BD Rhapsody system and AbSeq assays will be
showcased at this year's AGBT Precision Health and ASHG
conferences.
These new products build on BD's 40-year history of providing
solutions for single cells using flow cytometry. With the BD
Rhapsody system, researchers are able to easily discover both the
gene expression and protein markers that more completely identify
their cell population of interest.
Join BD at the AGBT meeting on Friday,
Sept. 15 from 6:30 to 8:30
p.m. or on Saturday, Sept. 16
from 12:45 to 1 p.m. in the Camelback
Ballroom for the workshop, BD Rhapsody system and AbSeq:
Simultaneous RNA and protein analysis on tens of thousands of
single cells.
More information on the BD Rhapsody system and the new BD
single-cell multiplexing assays is available at
bd.com/Rhapsody.
The BD Rhapsody system is for research use only and not for
diagnostic or therapeutic use. For more information, contact BD at
+1 650.665.2400.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has more nearly 50,000
associates across 50 countries who work in close collaboration with
customers and partners to help enhance outcomes, lower health care
delivery costs, increase efficiencies, improve health care safety
and expand access to health. For more information on BD, please
visit bd.com.
Contacts:
|
|
Gwen
Gordon
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.812.3724
|
201.847.5378
|
gwen.gordon@bd.com
|
Monique_Dolecki@bd.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bd-expands-genomics-portfolio-with-new-single-cell-platform-for-rna-expression-analysis-300517447.html
SOURCE BD (Becton, Dickinson and Company)